Return Home About Us Solutions Projects Technologies Contact Us

Nuclear Medicine Project


Mr. Willar will oversee the financial reconstruction of the Nuclear Power Plant in Idaho for the purpose of setting up treatment facilities for deep-seated inoperable brain tumors utilizing Boron Neutron Capture Therapy. When finished and set into operation it will be the only privately owned and operated nuclear medical facility in the world. The new facility will also supply all of North America with Molly 99 radioactive isotopes for research, medical and industrial use.

The seven hundred and fifty million dollar project will also fund several charitable projects including world wide indigent access, medical scholarships, and grants to research and development in the field of Neutron Boron Technologies. The new facilities will include a hospital, state of the art laboratory, out patent clinic and living quarters.

On going research shows promise for prostate, liver and breast cancer. Boron Neutron Capture Therapy (BNCT) will impact some fifty to sixty thousand lives a year world wide for deep-seated inoperable brain tumors.

It is expected to take eighteen months to two years before the facilities are fully operational. A world-class association of Neural Surgeon and Nuclear Scientist in the field of BNCT will head up the IBT&IC Medical Advisory Team. Mr. Willar will assume his new responsibilities in January 2001.


Presently there is no cure for persons suffering from glioblastoma or other malignant brain tumors. Over 7000 people die annually in the U.S. alone from this disease and many others suffer substantial reduction in quality of life from such brain tumors. The average life expectancy for persons diagnosed with this disease is only 9 months! Over 70,000 new brain tumors of all types are diagnosed each year in this country, most of which could be effectively treated with BNCT.

BNCT, Boron Neutron Capture Therapy, is a totally unique approach to cancer treatment, currently perfected for brain tumors and melanoma, with possible future applications to other cancers, such as breast, and prostate. It uses an intravenous injection of boron, which concentrates in the cancer cells rather than the normal cells. Neutrons from a nuclear reactor are then applied; causing a lethal fission reaction that kills the boron containing cancer cells but does not damage the normal cells.

The initial concept of BNCT was developed in the 1950's by Boston neurosurgeon Dr. William Sweet. However, the science was not yet advanced enough. One of his students, Dr. Hiroshi Hatanaka, went on to develop BNCT further in Japan where he was able to cure some patients with malignant brain tumors, who went on to live normal lives for over 20 years. Building on these results, US researchers began doing more work on BNCT in the late 1980's, and treating the first human US patient in 1993.

FDA clinical trials of BNCT have been done, using reactors at Brookhaven National Laboratory, and MIT in Boston. So far the results of these trials have been promising. After hundreds of laboratory animal tests, 16patients were treated at Brookhaven in 1995 and 1996.No patients had any harmful side effects. The FDA considered this Phase I trial adequate proof of safety and approved advancement to Phase II for proof of effectiveness, currently in progress. At MIT, researchers are treating both glioblastoma brain tumors and melanoma tumors with BNCT. So far their results are promising. Patients are living longer with fewer side effects than with conventional treatment.

In November, 1997, a European BNCT Consortium began treating patients using a reactor at Petten, Netherlands. In 1999, BNCT patient treatment began at a reactor in Finland. In Studsvik, Sweden, a reactor is currently being readied to begin BNCT patient treatments. Thailand is currently developing a BNCT treatment program. While drugs are now available to selectively carry boron into brain tumors and melanoma, there is further research being done on developing drugs to selectively carry boron into other cancers such as breast, prostate and lung. Once these are available the same neutron beam could treat those cancers as well, with potentially over a hundred thousand cancer patients a year benefiting from BNCT.

The best reactor in the world for BNCT is the Power Burst Facility, (PBF) located at the Idaho National Engineering and Environmental Laboratory, (INEEL), of the US Department of Energy (DOE). This reactor has the power to penetrate beyond the center of the brain as well as do the entire treatment in 3 to 6 minutes compared to 40 minutes at Brookhaven and several hours at MIT. In 1994 the Idaho Brain Tumor Center leased the PBF reactor from DOE for 30 years, for the purpose of converting it into a large scale brain tumor treatment center capable of treating up to ten thousand patients a year. Although the original lease expired before adequate private funding could be obtained, the DOE would still like to see this humanitarian, "swords into plowshares" conversion take place as soon as adequate funds are available. It is an outpatient treatment, completed in a single day, requiring neither hospitalization nor surgery. Our goal is to make this life saving treatment available quickly to thousands of patients who are currently dying at the rate of over 20 deaths a day!

Idaho Brain Tumor Center plans to convert this idle surplus nuclear reactor to a state-of the-art cancer treatment center. Initially malignant brain tumor patients will be treated from all over the country. As additional drugs are developed to carry boron into other cancers the center will treat patients with lung, prostate, pancreas and breast cancer as well. Given that the Japanese, using a small, weak, reactor have been able to get a 60% cure rate on tumors considered hopeless in the US, we expect to be able to improve that to a better than 80% cure rate with the powerful PBF reactor.

In addition to benefiting cancer patients, this project has environmental advantages. The DOE has a large supply of nuclear fuel for this reactor in storage, which we can use at no cost. At the same time, by burning up this fuel we save the government from having to otherwise bury it in the ground or continue to store it at risk to the environment.

In addition to funding the costs of converting the reactor to a cancer treatment center, the foundation will also fund three additional related humanitarian needs:

Providing funds for the treatment of indigent cancer patients who need BNCT treatment. It is very important to the founder of IBT&IC that cancer patients needing BNCT treatment receive it even if they have no insurance or lack enough money to pay for the entire cost of treatment. In addition, funds will be provided for transportation to the center, and also for a family member to accompany the patient. Meals and lodging for patient and family member will also be provided. Since IBT&IC will be the only large scale source of BNCT treatment in this country for the next decade or more, it is important that financial provisions for treating indigent and uninsured patients be made early in the project.

Providing funds for research in improving the technology of BNCT treatment, including the development of new drugs that carry boron into other tumors, such as breast, prostate, and lung cancer, to enable these cancers to also be treated with BNCT. There are currently drugs available for brain tumors, and melanoma. There is research going on in several universities to develop new boron drugs to treat other tumors with BNCT. This research, while expensive, holds the promise of greatly expanding the number of cancer patients who can be treated with BNCT. The Foundation plans to fund many research projects of scientists and doctors who have been working on this development for years.


The Foundation plans to promote education programs that inform the public, patients and families, government officials, and health care professionals about new developments in BNCT treatment of cancer patients. These programs would include publications, scientific meetings, public forums, patient support groups, magazine articles, and radio and television appearances by BNCT experts. It is important for this information to be widely shared to bring the benefits of BNCT to the public as soon as possible.

We anticipate the need to raise at least one hundred fifty million dollars to allow us to move forward quickly in achieving these goals. With hundreds of thousands of cancer deaths each year we must move this technology from the laboratory to the patients without delay.

The Company

IBT&IC, and its associated non-profit foundation, (IBT&ICF) Idaho Brain Tumor Cancer Foundation will have unrestricted use of the PBF reactor during the lease. The only costs will be modification construction, license fees, operating expenses and maintenance. The DOE will provide site security. The PBF reactor has been maintained in an operational ready status since 1986 with an annual budget of $2.5 million. The reactor has ample fuel and additional supplies are available at INEEL.

The mission statement for IBT&IC is two-fold: Provide the most comprehensive, compassionate and cost-effective BNCT treatment facility in the world for brain tumor patients, and provide a cost-effective reliable source of medical isotopes for U.S. nuclear medicine.

The Markets

Currently over 70,000-brain tumor patients are diagnosed in the U.S. each year, 75% of whom could benefit from BNCT. The average cost of treatment per patient is about $100,000. Since the PBF reactor produces a powerful source of high quality neutrons, it will only require 3 minutes of exposure time per patient to do the BNCT treatment. Therefore, with one shift per day, IBT&IC can treat over 3,000 patients per year. With three shifts per day, IBT&IC could treat 10,000 patients per year.

During the operation of the PBF reactor, Mo99 will be produced in 6day cycles. Production capacity will exceed one and a half times the current consumption of Mo99 in the entire Western Hemisphere, and provide a revenue stream of over $100 million. Other medical isotopes such as Iodine 131 (1-131) and Xenon 133 (Xe-13~) are produced as a by-product of Mo99 production. A biotech pharmaceutical company has contacted IBT&IC because they project a need for $40-50 million in 1-131isotope. The end user market for nuclear medicine in the U.S. today is estimated to be over $3 billion.

Competitive Position

There are only five reactors known in the world, which can produce the quality of neutrons required for BNCT. The PBF reactor is the most powerful and considered to be the best source.

Nordion International supplies 100% of the U.S. market for Mo99. Nordion has announced plans to build replacement reactors in Canada at an estimated cost of $140 million. Nordion has also indicated they win increase the price of Mo99 by 300% over a few years. In January 1996,they increased the price by 400.10, and increased another 400.10 in April 1997. That is why we believe the U.S. market for Mo99 will be over $150 million very soon.

The Future

Long-term development calls for the company to develop two business lines. BNCT cancer treatment has been discussed. There are 70,000 new brain tumor patients diagnosed in the U.S. each year, at least 75% of whom could benefit from BNCT.

Click Here to See Diagram



Copyright © 2012